hypogonadism%20in%20males%20-%20late-onset
HYPOGONADISM IN MALES - LATE-ONSET
Late onset hypogonadism is defined as clinical and biochemical syndrome characterized by older age, set of typical symptoms, and deficiency in serum testosterone levels.
The quality of life may be decreased and multiple organ systems may be adversely affected.
Prior to the start of testosterone substitution, there should be confirmation of low serum testosterone and a confirmation of need based on clinical findings.
Only if the potential benefit exceeds the risk, then replacement testosterone should be started.

Hypogonadism%20in%20males%20-%20late-onset Management

Follow Up

  • The patient should be monitored carefully (by monthly check-up every 3 months) for the development of adverse effects

At 1 Month & 3 monthly therafter

  • Follow up w/ patients to assess that the desired testosterone level is achieved
    • Optimal serum testosterone level for efficacy is unknown
    • It is generally recommended that mid to lower young adult levels may be appropriate as the therapeutic goal 
  • Evaluate the patient for complications/adverse effects & determine if symptoms are improving

During 1st Year of Therapy

  • Perform prostate exam, PSA, hematocrit every 3 months
    • Hematocrit >54% requires dose reduction or temporary medication discontinuation
    • If the PSA increases >0.75 ng/mL over 2 consecutive controls or a PSA level abnormal for age (>4 ng/mL), further exam & eventual biopsy may be needed
  • Plasma lipid determinations at the 3rd & 6th month of therapy
  • Liver function test, urinalysis & measurement of bone markers may be done at the 6th month

At 1 Year

  • Repeat all previous tests done on the 6th month
  • Blood glucose control should be evaluated by fasting blood glucose (FBG), post-prandial glucose (PPG) or HbA1c
  • After the 1st year, follow-up may be done every 6 months for 2 years & annually thereafter
Editor's Recommendations
Most Read Articles
Elvira Manzano, Yesterday
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, Yesterday
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.